IPP Bureau
Bayer acquires Noria and PSMA Therapeutics
By IPP Bureau - June 07, 2021
Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)
Jubilant Pharmova posts Q4FY21 consolidated PAT of Rs. 213.90 Cr
By IPP Bureau - June 05, 2021
The company is doubling its chemistry research capacity that should commission by Q2'FY22
Lupin launches generic version of Brovana in US
By IPP Bureau - June 04, 2021
Arformoterol Tartrate Inhalation Solution is for treatment of bronchoconstriction
Govt. to procure 30 Cr COVID-19 vaccine doses from Biological-E
By IPP Bureau - June 03, 2021
These vaccine doses will be manufactured and stockpiled by the company from August-December 2021
Panacea Biotec posts consolidated Q4FY21 loss of Rs. 54.14 crore
By IPP Bureau - June 03, 2021
The company reported total income of Rs.634.79 crores during the 12 months period ended March 31, 2021
Lupin announces U.S. FDA acceptance for pegfilgrastim biosimilar application
By IPP Bureau - June 03, 2021
Pegfilgrastim has estimated annual sales of USD 3.66 billion in the U.S. (IQVIA MAT December 2020).
Sun Pharma and Ferring Pharmaceuticals to introducing CARITEC in India
By IPP Bureau - June 03, 2021
Sun Pharma is granted rights for co-marketing of the drug in India in the private market under the brand name CARITEC
Lonza to expand manufacturing drug substance for COVID-19 Vaccine Moderna
By IPP Bureau - June 03, 2021
Production line at Lonza’s site in Geleen will complement the existing production network and support the manufacture of up to an additional 300 million doses per year
Haffkine Biopharma to produce 22.8 Cr doses of Covaxin
By IPP Bureau - June 03, 2021
For undertaking production, the company has been provided a Rs. 65 crore grant by the centre and Rs. 94 crore from the government of Maharashtra
Lupin to foray into the digital healthcare space
By IPP Bureau - June 03, 2021
The company recently incorporated a new entity in the name of Lupin Digital Health Limited
Glenmark Pharmaceuticals launches Rufinamide Tablets USP, 200 mg and 400 mg
By IPP Bureau - June 02, 2021
The Banzel Tablets, 200 mg and 400 mg market2 achieved annual sales of approximately $285.3 million.
Progress on new ventures key for Aurobindo Pharma: ICICI Securities
By IPP Bureau - June 02, 2021
Aurobindo has one of the most enduring generics ecosystems among peers
Lasa Supergenerics FY21 profit up 521%
By IPP Bureau - June 02, 2021
Revenues from operations for FY21 stood at Rs. 202.38 crore as compared to 167.27 crore, up by 21%
Shilpa Medicare Q4FY21 consolidated PAT at Rs. 7.82 Cr
By IPP Bureau - June 01, 2021
The company has posted net profit of Rs.147.78 crores for the 12 months period ended March 31, 2021
Marksans Pharma Q4 FY21 profit up 86%
By IPP Bureau - June 01, 2021
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
